Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Cash from Financing Activities: 2014-2024

Historic Cash from Financing Activities for Soleno Therapeutics (SLNO) over the last 11 years, with Dec 2024 value amounting to $213.0 million.

  • Soleno Therapeutics' Cash from Financing Activities rose 15.05% to $16.3 million in Q4 2018 from the same period last year, while for Dec 2018 it was $17.8 million, marking a year-over-year decrease of 40.31%. This contributed to the annual value of $213.0 million for FY2024, which is 18.33% up from last year.
  • As of FY2024, Soleno Therapeutics' Cash from Financing Activities stood at $213.0 million, which was up 18.33% from $180.0 million recorded in FY2023.
  • In the past 5 years, Soleno Therapeutics' Cash from Financing Activities ranged from a high of $213.0 million in FY2024 and a low of -$128,000 during FY2021.
  • Over the past 3 years, Soleno Therapeutics' median Cash from Financing Activities value was $180.0 million (recorded in 2023), while the average stood at $135.7 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first tumbled by 100.24% in 2021, then soared by 11,109.38% in 2022.
  • Yearly analysis of 5 years shows Soleno Therapeutics' Cash from Financing Activities stood at $53.7 million in 2020, then plummeted by 100.24% to -$128,000 in 2021, then skyrocketed by 11,109.38% to $14.1 million in 2022, then surged by 1,177.46% to $180.0 million in 2023, then rose by 18.33% to $213.0 million in 2024.